TELA Bio Inc (TELA) gains 2.94% for July 21

Equities Staff  |

TELA Bio Inc (NASDAQ: TELA) shares gained 2.94%, or $0.45 per share, to close Wednesday at $15.77. After opening the day at $15.34, shares of TELA Bio fluctuated between $15.77 and $15.39. 7,756 shares traded hands a decrease from their 30 day average of 72,913. Wednesday's activity brought TELA Bio’s market cap to $227,725,297.

About TELA Bio Inc

TELA Bio Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is committed to providing patients with advanced, economically effective biologic material repair solutions to patients to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.

Visit TELA Bio Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on TELA Bio Inc and to follow the company’s latest updates, you can visit the company’s profile page here: TELA Bio Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Market Movers

Sponsored Financial Content